OP0100 OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB
H. Wadström, T. Frisell, J. Askling on behalf of The ARTIS study group. Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden Background: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute an important aspect of the safety of biologics as used in Rheumatology, including agents targeting TNF, CD20 and IL6, and immunomodulation using CTLA4. Whereas previous reports concerning TNF inhibitors (TNFi) and risk of malignancies in rheumatoid arthritis (RA) have mostly been reassuring, risks with other biological disease modifying anti-rheumatic drugs (bDMARDs) are less studied. Objectives: To assess the risk of malignancies in patients with RA treated with bDMARDs. Methods: Through linkages of Swedish national and population-based registers we assembled cohorts of patients with RA initiating (Jan 2006 through Dec 2014) a first ever treatment of tocilizumab, abatacept, rituximab, or a TNFi, one cohort of patients initiating a second TNFi, one cohort of biologics-naïve csDMARD Abstract OP0101 - Table 1 Infection Outcome
Abatacept ( treated RA. Through linkage with the Swedish Cancer Register information on incident cancers was collected. Outcomes were defined as a first ever solid or hematologic malignancy excluding non-melanoma skin cancer (NMSC) during follow-up. Patients with a previous malignancy were excluded. Patients were followed from treatment start until death, emigration, outcome or end of follow up (Dec 2014). Hazard ratios were calculated using Cox-regression adjusted for age, sex, educational level, comorbidities, sero-positivity, number of hospitalizations and days spent in inpatient care, use of prednisolone at baseline, use of nonsteroidal anti-inflammatory drugs (NSAIDs) at baseline, number of prescription drugs at baseline, and sick leave and disability (yes/no) the year before cohort entry. Results: Adjusted for age, sex, disease-and treatment characteristics (see above), and educational level, there were no statistically significant differences in risk of a first solid or hematologic malignancy between initiators of tocilizumab, abatacept, rituximab, or a first-or second TNFi, and RA patients treated with csDMARDs. Background: Opportunistic infections (OI) during treatment with abatacept (ABA) have been previously reported but are lacking a comprehensive analysis. Objectives: To present the overall incidence rates of OI and herpes infections observed in patients (pts) receiving ABA using combined clinical trial data. Methods: OI adverse events were summarized from 16 clinical trials (both placebo-controlled and cumulative abatacept exposure); all pts randomized to placebo were on a non-biologic DMARD. Incidence rates (per 100 person-years [p-y]) were calculated by the number of pts experiencing the first event divided by the total number of p-y of exposure. The p-y of exposure was censored at the time of the first event, death, discontinuation or end of study. Random effects metaregression was performed across the trials to estimate the frequency of OI after adjusting for between-study heterogeneity. OI were identified using a pre-specified list in the setting of biologic therapy for patients with RA. Criteria for consideration were based on type, location of the infection and causing organism. Excluded from the list were non-specific infections caused by organisms considered to be opportunistic, but common in the general population. Results: A total of 7044 pts with RA with ∼21,330 p-y of ABA exposure were included in the cumulative randomized trial data (Table) . The frequency of OI
